{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:04:13Z","timestamp":1784826253445,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck & Co, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with cystic fibrosis (pwCF) are particularly susceptible to respiratory infections, including those caused by multidrug-resistant (MDR) pathogens. Ceftolozane\/tazobactam (C\/T) is an antibacterial agent combination active against MDR gram-negative bacteria that has shown promising results in isolates from pwCF. This subanalysis is the first extensive observation of real-world C\/T use in pwCF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The multicenter observational CONDUCT study included consecutive patients, some with cystic fibrosis, who received \u22651 dose of C\/T at 28 centers throughout France. Patients were treated according to hospital standards and followed up until the end of C\/T treatment (EOT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 260 patients who had received \u22651 dose of C\/T, 63 were pwCF, including 12 with previous lung transplant. The median age was 34 years and 55.6% of patients were female. Pseudomonas aeruginosa was the most frequently isolated pathogen (n = 40\/41 [97.6%]). Most tested P aeruginosa strains (n = 65\/73 [91.5%]) and all other isolated strains (Escherichia coli, Citrobacter koseri, Proteus mirabilis, and Serratia marcescens) were susceptible to C\/T. Most patients completed the treatment duration, including those with historical \u03b2-lactam hypersensitivity. Reasons for stopping treatment were planned EOT and improvement in condition; overall, 88.9% of patients (n = 56\/63) experienced improvement in condition. No new safety signals were identified. Mean forced expiratory volume in 1 second improved from 1.33 L to 1.47 L before and after C\/T treatment, respectively (n = 52; P = .057).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>C\/T treatment was well tolerated and effective in pwCF, including those with previous \u03b2-lactam hypersensitivity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae391","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:19:20Z","timestamp":1723004360000},"source":"Crossref","is-referenced-by-count":6,"title":["Ceftolozane\/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[{"name":"Respiratory Medicine and National Cystic Fibrosis Reference Center, H\u00f4pital Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9 and Institut Cochin, Inserm \u00a0 Paris , France"},{"name":"ERN-LUNG cystic fibrosis Core Network , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bourge","sequence":"additional","affiliation":[{"name":"MSD France , Puteaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Mackosso","sequence":"additional","affiliation":[{"name":"MSD France , Puteaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Parquin","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Soins Intensifs Respiratoires Groupe de Transplantation Pulmonaire, H\u00f4pital Foch , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"2024082915070874100_ofae391-B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"key":"2024082915070874100_ofae391-B2","author":"Vaincre la Mucoviscidose"},{"key":"2024082915070874100_ofae391-B3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2024082915070874100_ofae391-B4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/archdischild-2013-304400","article-title":"Recent advances in the management of cystic fibrosis","volume":"99","author":"Davies","year":"2014","journal-title":"Arch Dis Child"},{"key":"2024082915070874100_ofae391-B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front Pharmacol"},{"key":"2024082915070874100_ofae391-B6","author":"Orenti"},{"key":"2024082915070874100_ofae391-B7","doi-asserted-by":"crossref","first-page":"e00138-18","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2024082915070874100_ofae391-B8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1309\/KJRPC7DD5TR9NTDM","article-title":"Mucoid Pseudomonas in cystic fibrosis","volume":"128","author":"Pritt","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2024082915070874100_ofae391-B9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcf.2005.01.003","article-title":"Lung transplantation for cystic fibrosis: 6-year follow-up","volume":"4","author":"Quattrucci","year":"2005","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/jcm10061275","article-title":"Bacterial re-colonization occurs early after lung transplantation in cystic fibrosis patients","volume":"10","author":"Holm","year":"2021","journal-title":"J Clin Med"},{"key":"2024082915070874100_ofae391-B11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jcf.2023.05.017","article-title":"Investigating Pseudomonas aeruginosa population structure and frequency of cross-infection in UK cystic fibrosis clinics\u2014a reference laboratory perspective","volume":"22","author":"Kenna","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics12020217","article-title":"Antibiotic resistance in patients with cystic fibrosis: past, present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2024082915070874100_ofae391-B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/apm.13331","article-title":"Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"131","author":"Katzenstein","year":"2023","journal-title":"APMIS"},{"key":"2024082915070874100_ofae391-B14","author":"Cystic Fibrosis Foundation"},{"key":"2024082915070874100_ofae391-B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jcf.2022.10.005","article-title":"New concepts in antimicrobial resistance in cystic fibrosis respiratory infections","volume":"21","author":"Drevinek","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciz364","article-title":"Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections","volume":"69","author":"Waters","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024082915070874100_ofae391-B17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2019.10.006","article-title":"Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices","volume":"19","author":"Zemanick","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B18","author":"European Medicines Agency"},{"key":"2024082915070874100_ofae391-B19","author":"US Food and Drug Administration"},{"key":"2024082915070874100_ofae391-B20","author":"European Medicines Agency"},{"key":"2024082915070874100_ofae391-B21","author":"US Food and Drug Administration"},{"key":"2024082915070874100_ofae391-B22","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/phar.1825","article-title":"Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"36","author":"Vickery","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2024082915070874100_ofae391-B23","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1128\/AAC.00705-16","article-title":"Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis","volume":"60","author":"Ang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024082915070874100_ofae391-B24","doi-asserted-by":"crossref","first-page":"e00830","DOI":"10.1016\/j.idcr.2020.e00830","article-title":"Ceftolozane\/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa","volume":"21","author":"Romano","year":"2020","journal-title":"IDCases"},{"key":"2024082915070874100_ofae391-B25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s10096-021-04218-1","article-title":"Ceftolozane\/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series","volume":"40","author":"Ottino","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024082915070874100_ofae391-B26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.idnow.2021.05.003","article-title":"Real-world evaluation of ceftolozane\/tazobactam therapy and clinical outcomes in France","volume":"51","author":"Castan","year":"2021","journal-title":"Infect Dis Now"},{"key":"2024082915070874100_ofae391-B27","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"2024082915070874100_ofae391-B28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1164\/rccm.201903-0576LE","article-title":"Impact of a reduction in susceptibility testing for Pseudomonas aeruginosa in a cystic fibrosis program","volume":"201","author":"Ponce","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024082915070874100_ofae391-B29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcf.2021.12.001","article-title":"Low body mass index as a barrier to lung transplant in cystic fibrosis","volume":"21","author":"Jennerich","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B30","doi-asserted-by":"crossref","first-page":"17421","DOI":"10.1038\/s41598-020-74502-1","article-title":"Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry","volume":"10","author":"Earnest","year":"2020","journal-title":"Sci Rep"},{"key":"2024082915070874100_ofae391-B31","first-page":"55","article-title":"A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis","volume":"20","author":"Harun","year":"2016","journal-title":"Paediatr Respir Rev"},{"key":"2024082915070874100_ofae391-B32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/thx.2004.027953","article-title":"Antibiotic allergy in cystic fibrosis","volume":"60","author":"Parmar","year":"2005","journal-title":"Thorax"},{"key":"2024082915070874100_ofae391-B33","doi-asserted-by":"crossref","first-page":"220154","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2024082915070874100_ofae391-B34","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2024082915070874100_ofae391-B35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with cystic fibrosis: a grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"key":"2024082915070874100_ofae391-B36","author":"Vertex Pharmaceuticals Incorporated"},{"key":"2024082915070874100_ofae391-B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024082915070874100_ofae391-B38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ajhp\/zxz011","article-title":"Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis","volume":"76","author":"Davis","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2024082915070874100_ofae391-B39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/antibiotics11040458","article-title":"Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024082915070874100_ofae391-B40","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/ejhpharm-2019-002093","article-title":"Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study","volume":"27","author":"Raby","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2024082915070874100_ofae391-B41","doi-asserted-by":"crossref","first-page":"dlab141","DOI":"10.1093\/jacamr\/dlab141","article-title":"Assessment of ceftolozane\/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy","volume":"3","author":"Jamieson","year":"2021","journal-title":"JAC Antimicrob Resist"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae391\/58874890\/ofae391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae391\/58874890\/ofae391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:52:39Z","timestamp":1724964759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae391\/7728194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae391","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,30]]},"article-number":"ofae391"}}